What Exactly Are Investors Buying? The Risks Behind the Wellbeing Investment Proposition
The Men Behind Wellbeing — Chapter Eleven
Wellbeing International Foundation is raising private capital to fund research and expansion. But after ten chapters following the people, science, patents and corporate history behind the organisation, a more urgent question emerges. Before anyone invests, can they establish exactly what they are buying, which entity owns the assets, what protects the technology, and what happens to their money if the scientific or commercial proposition fails?
For ten chapters, I have deliberately avoided telling anyone whether they should or should not invest in Wellbeing International Foundation.
That decision belongs to the investor.
But investigation changes the questions an investor should ask.
At the beginning of this series, the proposition could appear relatively straightforward.
An organisation working in regenerative biotechnology.
A scientist with decades of experience.
A Cell-Free Therapy built around extracellular-vesicle biology.
International clinical relationships.
Research.
Patients.
And now private investment intended to finance the next stage of development.
But after following the history behind that proposition, the picture requiring due diligence has become considerably more complicated.
We have found historical patents.
We have found an earlier biotechnology company.
We have found insolvency.
We have found questions concerning intellectual-property ownership.
And now we have a private investment round whose detailed financial terms are not publicly disclosed.
None of those things individually proves that the investment is unsound.
But taken together, they create a level of uncertainty that a prospective investor should resolve before money changes hands.
Wellbeing Is Raising Money Now
This isn't a hypothetical discussion.
In March 2026, Wellbeing announced that it had closed the opening tranche of its current capital round.
It also confirmed that the round remained open.
According to Wellbeing, the capital is supporting continued research, expansion of clinical relationships in the United States and Europe, documentation work and operating capacity. (Wellbeing International Foundation)
Wellbeing also says it has historically been financed through a combination of:
private investment;
patient revenue;
and:
selective philanthropy. (Wellbeing International Foundation)
So prospective investors are being asked to place capital behind an organisation whose future is linked to both scientific development and commercial execution.
That is inherently different from buying shares in a mature company with decades of audited earnings and readily valued assets.
This is biotechnology.
And biotechnology investment can be highly uncertain.
The First Question Should Be the Simplest: What Am I Buying?
This should be easy to answer.
Yet publicly, it isn't.
If someone invests money into Wellbeing, what exactly do they receive?
Shares?
Preference shares?
Debt?
Convertible debt?
A revenue participation?
An interest in another legal entity?
What percentage of the organisation does the investment represent?
What voting rights accompany it?
What liquidation rights exist?
What happens during another financing round?
Can the investor be diluted?
And perhaps most importantly:
Which legal entity actually receives the investment?
Wellbeing itself says that the specific terms, amounts and participating investors in the 2026 round are private and are held by its legal and finance team. (Wellbeing International Foundation)
That is not proof that those answers aren't available to prospective investors.
Wellbeing explicitly says investor materials are shared privately with parties having a legitimate interest.
But it means those answers cannot be established from the public announcement alone.
Any prospective investor should therefore obtain them before investing.
Risk One: The Investment Structure Is Not Publicly Transparent
Private companies are not required to publish everything a listed company publishes.
There is nothing inherently unusual about confidential investment terms.
But confidentiality increases the importance of individual due diligence.
A prospective investor should not rely upon a news announcement that a tranche has successfully closed as evidence that the investment itself has been independently validated.
Other people investing does not tell you:
what price they paid;
what protections they received;
what due diligence they conducted;
what representations were made to them;
or whether their investment terms are the same as yours.
The phrase “investors have already invested” is not a substitute for examining the documents yourself.
Risk Two: What Is the Company Actually Worth?
Before purchasing an interest in any private company, an investor should understand the valuation.
Suppose someone invests £100,000.
Without knowing the valuation, that number tells us almost nothing.
£100,000 invested at a £2 million valuation is completely different from £100,000 invested at £50 million.
So investors need to ask:
What is the pre-money valuation?
What is the post-money valuation?
And most importantly:
How was that valuation calculated?
Was it based on revenue?
Profit?
Projected patient numbers?
Intellectual property?
Comparable biotechnology companies?
Research?
Previous investment rounds?
Or expectations concerning future commercialisation?
A valuation is not automatically unreasonable simply because it is high.
But the assumptions supporting it should be available for examination.
Risk Three: We Still Haven't Established What Wellbeing Owns
After Chapters Nine and Ten, this becomes particularly important.
Stephen Ray has a documented intellectual-property history involving microvesicles.
The original patent family identifies Lydac Neuroscience as the corporate assignee.
Today, Wellbeing promotes Cell-Free Therapy involving extracellular vesicles.
But our investigation has not yet established a complete public assignment trail transferring that historical patent family from Lydac to Wellbeing.
That does not prove Wellbeing lacks rights to CFT.
Modern CFT could involve later technology.
Wellbeing could possess licences.
It could rely upon proprietary know-how.
The historical patents may no longer matter.
But an investor shouldn't have to guess.
If intellectual property contributes materially to the valuation, the investor should see the documents establishing ownership or control.
Risk Four: What Is the Defensible Asset?
This may be the most important commercial question.
Imagine that the old Lydac patents are irrelevant.
Fine.
What protects CFT today?
If another laboratory or biotechnology organisation understands extracellular-vesicle biology, what prevents it developing a competing process?
Is the protection:
patents?
trade secrets?
exclusive licences?
manufacturing know-how?
clinical data?
contracts?
Stephen Ray's expertise?
Or some combination of these?
An investor needs to know what Wellbeing controls that a competitor cannot readily reproduce.
Because a promising scientific field and a defensible commercial business are not the same thing.
Risk Five: Key-Person Dependency
Suppose the real proprietary advantage isn't a patent.
Suppose it is Stephen Ray.
His accumulated knowledge.
His protocols.
His experience.
His understanding of how to produce the biological preparation.
That might be commercially valuable.
But it introduces key-person risk.
What happens if Ray leaves?
What happens if he becomes unable or unwilling to continue?
Does Wellbeing possess documented protocols allowing the process to continue independently?
Are his inventions contractually assigned?
Can he work with competitors?
Does Wellbeing have exclusive rights to future developments?
A business whose scientific value depends heavily upon one individual's knowledge presents a very different investment profile from one whose technology is securely owned and independently reproducible.
Risk Six: Scientific Evidence Is Still Developing
There is another distinction investors should understand.
Wellbeing now points to a peer-reviewed longevity pilot published in Frontiers in Aging.
That is a genuine peer-reviewed publication.
But it was a small pilot involving 14 participants who completed the study, and the intervention was multimodal.
Participants were not simply given CFT.
The programme incorporated multiple lifestyle and supplement interventions alongside two administrations of autologous cell-conditioned media.
There was no randomized placebo-controlled design separating the contribution of the different components.
That means the study is evidence worth examining.
It is not definitive proof that CFT itself produced the reported outcomes.
Wellbeing itself describes its approach as requiring long-term evidence accumulation. Its 2026 investment announcement says capital will continue supporting that work. (Wellbeing International Foundation)
For an investor, that means scientific validation should be treated as an evolving process rather than a completed one.
Risk Seven: Commercial Claims and Scientific Evidence Must Be Separated
This is particularly important in regenerative medicine.
There can be an enormous gap between:
a scientifically interesting mechanism
and:
a clinically proven commercial treatment.
Extracellular vesicles are a legitimate and substantial field of research.
That doesn't automatically validate every therapeutic use of them.
Likewise, evidence that extracellular vesicles participate in biological signalling does not automatically establish that a particular commercial preparation produces a claimed clinical outcome.
Investors should therefore ask:
Which claims are supported specifically by Wellbeing's own controlled clinical evidence?
Which rely upon broader extracellular-vesicle literature?
Which are based upon observational experience?
Which are based upon patient testimonials?
And which remain hypotheses under investigation?
Those categories should not be blended together when valuing the business.
Risk Eight: The Corporate Structure Matters
Wellbeing publicly identifies its headquarters as Hamilton, Bermuda, and its public professional profile describes the organisation as privately held. (LinkedIn)
There is nothing inherently problematic about a Bermuda-headquartered international organisation.
But jurisdiction matters enormously to an investor.
Which entity issues the investment?
Where is it incorporated?
What law governs the securities?
Where are shareholder disputes resolved?
Where are the assets located?
Where are the bank accounts?
Where is the intellectual property registered?
Where are contracts held?
Wellbeing's current website terms state that those website terms are governed by Bermuda law and provide for disputes under those terms to be handled in Bermuda. That does not necessarily establish the governing law of an investment agreement, which investors would need to confirm separately. (Wellbeing International Foundation)
These aren't administrative details.
They determine what rights an investor actually has when something goes wrong.
Risk Nine: The Historical Corporate Record Deserves Attention
Then we return to Lydac.
Andrew Chancellor was a director of Lydac Neuroscience when administrators were appointed in December 2018. Companies House records his appointment as director from November 2014, while the Gazette confirms Lydac entered administration on 17 December 2018. (Find and Update Company Information)
That does not establish misconduct by Chancellor.
Company failure happens.
But an investor performing due diligence on a chief executive should understand the history of previous ventures relevant to the same commercial field.
In this instance, it is particularly relevant because Lydac wasn't an unrelated restaurant, property company or retailer.
It was a biotechnology research company associated with Stephen Ray's earlier microvesicle intellectual property.
An investor should therefore understand what happened.
What caused the insolvency?
What did creditors lose?
What happened to the assets?
What lessons were learned?
And how is the present organisation structurally different?
Risk Ten: What Happens If the Research Doesn't Deliver?
This is the question every biotechnology investor eventually faces.
What if the science does not produce the commercial result expected?
What assets remain?
If Wellbeing owned enforceable patents, those patents might retain value.
If it owned proprietary technology, that technology might be licensed or sold.
If it possessed valuable clinical data, that data could potentially have commercial value.
But if much of the value lies in:
reputation;
future expectations;
key individuals;
patient relationships;
and emerging research;
then downside protection may look very different.
Investors need to understand the difference between potential future value and assets recoverable if the business fails.
Lydac's history makes that question especially relevant.
Risk Eleven: What Happens If More Money Is Needed?
Wellbeing describes its 2026 round as part of a longer-term funding cadence rather than an isolated event. (Wellbeing International Foundation)
That wording deserves attention from investors.
Biotechnology development can consume substantial capital.
If additional rounds are required:
Will existing investors be diluted?
Will they have pre-emption rights?
Could later investors receive preferential terms?
Could new share classes rank ahead of existing investors?
Is there a minimum capital requirement to reach the next scientific or commercial milestone?
What happens if the next round cannot be raised?
These questions should be answered before investing in the current round—not afterwards.
The Central Problem: Too Many Important Questions Depend on Private Documents
This is where my concern has increased during this investigation.
Not because one single document proves Wellbeing is an unsafe investment.
It doesn't.
The concern comes from how many important questions cannot presently be answered from the public record.
We still need clarity around:
the investment instrument;
the valuation;
the capital structure;
shareholder rights;
financial performance;
cash requirements;
intellectual-property ownership;
licensing;
key-person dependency;
and the relationship between historical and present technology.
Some of these answers may exist in Wellbeing's private investor documentation.
Wellbeing says investor materials are maintained separately and provided to parties with legitimate interest. (Wellbeing International Foundation)
If those documents resolve the questions, that is important.
But a prospective investor should insist on seeing them.
Do Not Invest in the Story. Invest in the Documents.
This is perhaps the single most important lesson from the last ten chapters.
A compelling story is not due diligence.
Thirty years of scientific experience is not an IP schedule.
A patent history is not proof of present ownership.
A peer-reviewed pilot is not proof of commercial success.
Testimonials are not audited revenue.
A successful investment tranche is not proof of valuation.
And sophisticated scientific language is not a substitute for understanding the legal entity receiving your money.
The investment decision should therefore be made from documents.
Not the narrative surrounding them.
What I Would Want Before Considering the Investment
Before assessing the proposition, I would want the prospective investor to obtain one complete due-diligence package containing:
the precise legal entity receiving the investment and its constitutional documents;
the current cap table and ultimate ownership structure;
the investment agreement and exact security being offered;
pre-money and post-money valuation and the assumptions supporting them;
recent financial statements, current management accounts, cash position and cash-burn projections;
details of existing debt and material liabilities;
the complete intellectual-property schedule, patent assignments and licences;
contracts governing Stephen Ray's existing and future intellectual property;
details of any material related-party arrangements;
the scientific and regulatory evidence specifically supporting the commercial CFT process;
details of the intended use of investment proceeds and milestones the current round is expected to finance;
investor dilution, preference, voting and liquidation rights; and
a clear explanation of the relationship, if any, between Lydac's historical technology and Wellbeing's present CFT.
Only then can the risk be assessed properly.
This Is Where My Investigation Has Changed
When I began investigating Wellbeing, I was primarily interested in whether the science stood up.
Eleven chapters later, my questions are different.
I want to know what investors legally own.
I want to know what Wellbeing owns.
I want to know what protects the technology.
I want to know what the company is worth and why.
I want to know how much capital it needs.
I want to know what happens if the research takes longer than expected.
And I want to know what remains for investors if the commercial proposition fails.
Those questions are not hostile.
They are exactly the questions an investment of this nature demands.
What We Are Not Saying
This investigation has not established that investors will lose their money.
It has not established that Wellbeing is insolvent.
It has not established that its valuation is unreasonable, because we have not publicly established what that valuation is.
It has not established that Wellbeing lacks intellectual-property rights.
And it has not established that the investment round is improper.
Those conclusions would go beyond the available evidence.
What the investigation has established is that there are substantial areas requiring verification before an investor could independently assess the proposition from the public record.
That distinction is important.
Questions I Would Put Directly to Wellbeing
If Wellbeing wants investors to understand the proposition, these questions should be straightforward to answer:
Which precise legal entity receives investment capital?
What security does an investor receive?
What is the current valuation?
What is the current cap table?
How much capital has been raised in the 2026 round?
How much additional capital is being sought?
What is the current annual cash requirement?
What intellectual property does the investment entity itself own?
Does it own or license the technology underlying CFT?
What relationship does that technology have to Stephen Ray's historical Lydac intellectual property?
What contractual rights does Wellbeing possess over Ray's present and future scientific developments?
What are the principal milestones the current capital is intended to reach?
And what happens to investors if those milestones are not achieved?
Those answers would tell us considerably more about the investment than another scientific presentation ever could.
Conclusion: The Risk Is in What We Still Cannot See
After ten chapters, I don't believe the most important investment question is:
“Could Cell-Free Therapy become commercially successful?”
Perhaps it could.
The more important question comes first:
“Can an investor establish exactly what they are buying and exactly what assets support its value?”
Right now, significant parts of that answer are not visible in the public record.
Wellbeing itself says the detailed financial information and investment materials are handled privately. (Wellbeing International Foundation)
That doesn't make the investment improper.
But it means nobody should substitute the public story for the private documentation.
The organisation operates in a developing area of biotechnology.
Its scientific evidence continues to develop.
Its historical intellectual-property lineage still contains unanswered ownership questions.
Its earlier corporate connections include Lydac Neuroscience, a biotechnology company that entered administration while Andrew Chancellor was a director. (Find and Update Company Information)
And the terms, amounts and participating investors in the current round are not publicly disclosed. (Wellbeing International Foundation)
Each fact has an innocent or ordinary possible explanation.
But together they create material due-diligence questions that should be resolved before an investor can sensibly judge the risk for themselves.
That is where this series changes direction.
We have followed the men.
We have followed the science.
We have followed the companies.
We have followed the patents.
Now we follow the investment itself.
Because before anyone writes a cheque, there is one question more important than all the promises about what this technology could become:
If everything doesn't go according to plan, what does the investor actually own?
Next: Chapter Twelve — Follow the Investment: Where Does Your Money Actually Go?
In Chapter Twelve, we follow the investment itself. Which legal entity receives the money? What does the investor receive in return? Where are the assets held? Who controls the capital? What rights does an investor have if another round is required—or if the business fails? The next stage is no longer about the scientific promise. It is about the financial structure underneath it.
Comments